Genetic Technologies company info

What does Genetic Technologies do?
Genetic Technologies (ASX:GTG), (NASDAQ:GENE) specializes in the development and commercialization of genetic risk assessment technology. The company's innovative projects revolve around DNA genotyping and analysis, aiming to provide predictive testing and assessment tools for diseases such as cancer. By harnessing advancements in genomics, Genetic Technologies seeks to revolutionize personalized healthcare, enabling more precise, predictive, and preventative care strategies. Their objective is to become a key player in the genetic testing market, offering solutions that can significantly improve patient outcomes through early detection and personalized treatment plans.
Genetic Technologies company media
Company Snapshot

Is Genetic Technologies a public or private company?

key
Ownership
Public

How many people does Genetic Technologies employ?

people
Employees
60

What sector is Genetic Technologies in?

pie chart
Sector
Health Care

Where is the head office for Genetic Technologies?

location pin
Head Office
Melbourne, Australia

What year was Genetic Technologies founded?

founded flag
Year Founded
1987
What does Genetic Technologies specialise in?
/Genetic Testing /Predictive Medicine /Breast Cancer Screening /Colorectal Cancer Test /Prostate Cancer Diagnostics /Lung Cancer Detection

What are the products and/or services of Genetic Technologies?

Overview of Genetic Technologies offerings
GeneType for Breast Cancer Risk Assessment, a genetic test providing personalized breast cancer risk.
GeneType for Colorectal Cancer Risk Assessment, a test offering personalized colorectal cancer risk.
GeneType for Cardiovascular Disease Risk Assessment, assessing individual risk for cardiovascular diseases.
GeneType Multi-Test, combining assessments for several cancers and diseases into a single test.
Consumer Initiated Testing (CIT) platform, enabling consumers to access genetic testing directly.
GeneType for Type 2 Diabetes Risk Assessment, identifying individual risk for developing Type 2 Diabetes.

Who is in the executive team of Genetic Technologies?

Genetic Technologies leadership team
  • Mr. Simon  Morriss
    Mr. Simon Morriss
    Chief Executive Officer
  • Mr. Carl S. Stubbings BSc
    Mr. Carl S. Stubbings BSc
    Chief Commercial Officer
  • Mr. Kevin  Camilleri
    Mr. Kevin Camilleri
    Chief Executive Officer of EasyDNA
  • Ms. Kathryn J. E. Andrews B.Com, CPA
    Ms. Kathryn J. E. Andrews B.Com, CPA
    Chief Financial Officer & Company Secretary
  • Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA
    Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA
    Consultant